In a report released today, Steven Halper from Cantor Fitzgerald reiterated a Buy rating on Tabula Rasa HealthCare (TRHC), with a price target of $99. The company’s shares opened today at $75.65.
Halper wrote:
“. We reiterate our Overweight rating and $99 12-month price target on TRHC shares. Rasa reported solid third quarter results, which were generally above our estimates and FactSet consensus. The company’s top-line beat was driven by recent acquisitions and higher pharmacy cost management (PCM) revenue due to a change regarding TRHC’s data aggregation partner. The company’s recent acquisitions contributed modestly to revenue. While TRHC provided general comments regarding 2019, it did not provide full guidance.”
According to TipRanks.com, Halper is a top 100 analyst with an average return of 20.4% and a 69.3% success rate. Halper covers the Services sector, focusing on stocks such as WellCare Health Plans, Tivity Health Inc, and Hms Holdings Corp.
Tabula Rasa HealthCare has an analyst consensus of Strong Buy, with a price target consensus of $90.17.
See today’s analyst top recommended stocks >>
The company has a one-year high of $91.16 and a one-year low of $26.02. Currently, Tabula Rasa HealthCare has an average volume of 354.8K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Tabula Rasa Healthcare, Inc. engages in the development of pharmaceutical software that optimizes medication regimens. It offers cloud-based applications, such as EireneRx and MedWise Advisor. The company was founded by Calvin H. Knowlton and Orsula V. Knowlton in April 2009 and is headquartered in Moorestown, NJ.
